- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 107
Minerva seeks divine outcome in $69m IPO
The Proteosys-backed pharmaceutical company, formed through a merger last year, is also set to raise $26m from a concurrent private placement to Johnson & Johnson.
Apr 11, 2014IDG makes $19m return as Tarena IPO generates almost $138m
IDG's China subsidiary and private equity firm Jafco both achieved partial exits as the education services provider went public raising $137.7m.
Apr 9, 2014Five9 counts the proceeds as its IPO raises $70m
The SAP-backed company, which is developing software to target the call centre market, has secured $70m in an initial public offering that could rise to $80.5m.
Apr 8, 2014Truecar to park in public markets
Truecar, an online provider of automotive pricing information that counts USAA and Capital One among its key shareholders, has targeted $125m in its initial public offering.
Apr 8, 2014Opower up after raising $116m from IPO
Opower, a GE-backed company that uses data analysis to make energy use more efficient, has raised $115.9m from an IPO that could close at more than $133m.
Apr 7, 2014Imprivata seeks authentic proceeds from $115m IPO
Healthcare authentication and communication company Imprivata, which has raised $32m from investors including SAP Ventures, aims to generate up to $115m from its initial public offering.
Apr 2, 2014AGTC sees $50m in proceeds from IPO
The biopharmaceutical company, which has investors including the corporate venturing subsidiaries of GlaxoSmithKline and MedImmune, has secured $50m from its initial public offering.
Mar 31, 2014Opower to generate up to $116m in IPO
The GE-backed energy management company has set the range for an initial public offering that could raise up to $115.9m.
Mar 26, 2014Versartis grows with $126m IPO
The Amunix-backed biopharmaceutical company could close its initial public offering at almost $145m, and will invest the proceeds in developing its lead drug candidate.
Mar 25, 2014About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


